Twelve-month longitudinal changes of NT-proBNP in patients with CHD not only remain strongly associated with subsequent adverse CVE but also improve risk classification, albeit only modestly, after its inclusion in a prognostic model containing well established risk factors. The gene discussed is NPPB; the disease is coronary artery disorder.